Louise holds a PhD in immunology from Imperial College London. Drawing on both her background in science and years of experience in drug discovery, development and commercialisation within academia, biotech and pharmaceutical organisations, she leads the commercial team at Health Innovation East to develop partnerships and support innovators to refine their business models and develop their products and services for implementation within the NHS and other healthcare systems.

Louise joined Health Innovation East from Johnson and Johnson Innovation, where she led partnership activities across Europe, Middle East and Africa to identify and incubate external assets and capabilities to advance the portfolio of the Immunology Therapy Area for Janssen. Louise is a board member of the Medtech Accelerator, Strategic Advisor to Enhanc3D Genomics and a mentor on a number of accelerator programmes including Start Codon. She is also a long-standing member of the British Society for Immunology and on the Editorial Board for Immunotherapy Advances journal.

In 2024, Louise joined the Babraham Research Campus as Chief Scientific & Innovation Officer. The focus of Louise’s role is to continue to strengthen the collaborative culture of the Campus in line with its vision to be one of the best places in the world to start, scale, nurture and grow a life sciences business. The immediate priorities include growing and broadening the Campus’ strategic partnerships with corporates, service providers, investors and trade organisations committed to accelerating and enabling vibrant UK life sciences researchers and companies – both those currently on Campus and new innovators which will be attracted as the Campus grows.

As the Babraham Institute’s Royal Society Entrepreneur in Residence, Louise will be working closely with researchers at the Babraham Institute, aiming to accelerate fundamental life science research for talent development, population health benefit and wealth creation.